

Region 4 providers – check out this scholarship opportunity – if you are interested, contact Bethany Gadzinski at gadzinsb@dhw.idaho.gov

The Center for Substance Abuse Treatment (CSAT) has granted travel awards to the Mountain West ATTC region to assist in the dissemination of NIDA/SAMHSA Blending initiatives. The Mountain West has scheduled a training on ***Buprenorphine Treatment for Young Adults*** in Jackson Hole, Wyoming on **June 23, 2010** and we have three travel awards available for each state in the Mountain West ATTC region. The training day will also include a ***Buprenorphine Treatment: Training for Multidisciplinary Addiction Professionals*** training. If you wish to distribute the flyer to treatment providers and solicit nominations, I have attached it for your convenience

In order to process the travel awards, I am to submit the following information to CSAT as soon as possible:

- Participant's name and contact information (email, phone, agency, address, city and state, zip code)
- Type of travel support needed (airfare, lodging, mileage, per diem)

The training will take place at the Snow King Resort in Jackson Hole.

See Next Page ↓



blending initiative

Location: Jackson Hole, Wyoming at the Snow King Resort
Date: June 23, 2010
Time: 8:30am - 4:30pm
Presenters: Mark Disselkoe and James Von Busch

Buprenorphine Treatment for Young Adults

Overview

The Buprenorphine Treatment for Young Adults Blending Team designed a training package which highlights the findings of the NIDA CTN study that compared longer term versus short-term buprenorphine/naloxone treatment in an outpatient setting. The 3-hour training program examines the prevalence of and treatment admission rates for nonmedical use of opioids among young adults; provides an overview of opioid use among young adults; explores and increases understanding of the results of new research on using buprenorphine to treat opioid addiction in young adults; and describes the implications of these findings for the treatment of opioid addiction in young adults.

Buprenorphine Treatment: Training for Multidisciplinary Addiction Professionals

Overview

Opioid abuse and addiction (e.g., heroin, OxyContin) remains a critical national public health concern. In 2002, tablet formulations of the medication Buprenorphine were approved by the Food and Drug Administration for the treatment of opioid addiction. In order to prepare the field to effectively integrated this new treatment, the Buprenorphine Treatment Blending Team developed an awareness training to disseminate information and enhance awareness among multidisciplinary (non-physician) addiction professionals about Buprenorphine treatment. This training is designed to provide a broad overview of the medication, its effects, and the role of non-physician practitioners in providing and supporting the treatment of individuals receiving this medication.

Questions

For questions regarding this Blending Initiative or upcoming Blending Products for your area, please contact the Mountain West ATTC, Wendy Woods at wwoods@casat.org.

This product is brought to you from the National Institute on Drug Abuse (NIDA) and relies on an innovative partnership with the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) known as the Blending Initiative. This initiative is NIDA's most recent effort to accelerate the dissemination of research-based drug abuse and addiction treatment findings into community-based practice. For more information on this Blending product, please go to <http://www.attcnetwork.org/explore/priorityareas/science/blendinginitiative/pam/>.



Mountain West
ATTC Unifying science, education
and services to transform lives.

Addiction Technology Transfer Center Network
Funded by Substance Abuse and Mental Health Services Administration

